Resource

Webinar: Advancing oligonucleotide drug development

Oligonucleotide therapeutics have emerged as a promising novel class of drugs to treat a wide range of diseases. The development of these therapeutics relies on the proper use of chemical building blocks called phosphoramidites to generate high‑quality oligonucleotides. This webinar discusses techniques for phosphoramidite synthesis, selection, and evaluation for the development of oligonucleotide drugs.

Learning objectives:

Optimizing phosphoramidites for oligonucleotide therapeutic development and manufacturing
Identifying phosphoramidite impurities and their potential impacts on oligonucleotide therapeutics

Speaker:

Gary Held
Staff Scientist, Analytical Development
Nucleic Acid Therapeutics
Thermo Fisher Scientific

Gary Held has been working in the phosphoramidite and nucleotide space at Thermo Fisher Scientific for almost 20 years. His expertise is in product testing and impurity identification analytical techniques such as LCMS and NMR. He has published several articles and application notes related to impurity formation and control in the amidite supply change and chemical synthesis. His prior experience includes leading analytical development and quality control teams for small molecule API manufacturers.

(*Indicates a mandatory field)

First Name*

Last Name*

Institution*

Telephone*

Email*

City*

Country/Region*

What type of oligos are you working on for oligo therapeutics development? (check all that apply)*

Antisense oligos (ASOs)

Aptamers

Guide RNAs (gRNAs)

Small activating RNAs (saRNAs)

Small interfering RNAs (siRNAs)

Other

Would you like to receive a quote for phosphoramidites?*

Yes

For Research Use Only. Not for use in diagnostic procedures.